These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22435740)

  • 1. (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.
    Boatman PD; Lauring B; Schrader TO; Kasem M; Johnson BR; Skinner P; Jung JK; Xu J; Cherrier MC; Webb PJ; Semple G; Sage CR; Knudsen J; Chen R; Luo WL; Caro L; Cote J; Lai E; Wagner J; Taggart AK; Carballo-Jane E; Hammond M; Colletti SL; Tata JR; Connolly DT; Waters MG; Richman JG
    J Med Chem; 2012 Apr; 55(8):3644-66. PubMed ID: 22435740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.
    Semple G; Skinner PJ; Gharbaoui T; Shin YJ; Jung JK; Cherrier MC; Webb PJ; Tamura SY; Boatman PD; Sage CR; Schrader TO; Chen R; Colletti SL; Tata JR; Waters MG; Cheng K; Taggart AK; Cai TQ; Carballo-Jane E; Behan DP; Connolly DT; Richman JG
    J Med Chem; 2008 Aug; 51(16):5101-8. PubMed ID: 18665582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a.
    Skinner PJ; Cherrier MC; Webb PJ; Shin YJ; Gharbaoui T; Lindstrom A; Hong V; Tamura SY; Dang HT; Pride CC; Chen R; Richman JG; Connolly DT; Semple G
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5620-3. PubMed ID: 17804224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a.
    Imbriglio JE; Chang S; Liang R; Raghavan S; Schmidt D; Smenton A; Tria S; Schrader TO; Jung JK; Esser C; Holt TG; Wolff MS; Taggart AK; Cheng K; Carballo-Jane E; Waters MG; Tata JR; Colletti SL
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4472-4. PubMed ID: 20615702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin stimulates adiponectin secretion through the GPR109A receptor.
    Plaisance EP; Lukasova M; Offermanns S; Zhang Y; Cao G; Judd RL
    Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E549-58. PubMed ID: 19141678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a).
    Boatman PD; Schrader TO; Kasem M; Johnson BR; Skinner PJ; Jung JK; Xu J; Cherrier MC; Webb PJ; Semple G; Sage CR; Knudsen J; Chen R; Taggart AK; Carballo-Jane E; Richman JG
    Bioorg Med Chem Lett; 2010 May; 20(9):2797-800. PubMed ID: 20363624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor.
    Kim HY; Jadhav VB; Jeong DY; Park WK; Song JH; Lee S; Cho H
    Arch Pharm Res; 2015 Jun; 38(6):1019-32. PubMed ID: 25599616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.
    Tang H; Lu JY; Zheng X; Yang Y; Reagan JD
    Biochem Biophys Res Commun; 2008 Oct; 375(4):562-5. PubMed ID: 18722346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia.
    Schmidt D; Smenton A; Raghavan S; Carballo-Jane E; Lubell S; Ciecko T; Holt TG; Wolff M; Taggart A; Wilsie L; Krsmanovic M; Ren N; Blom D; Cheng K; McCann PE; Gerard Waters M; Tata J; Colletti S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4768-72. PubMed ID: 19592242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.
    Shen HC; Ding FX; Raghavan S; Deng Q; Luell S; Forrest MJ; Carballo-Jane E; Wilsie LC; Krsmanovic ML; Taggart AK; Wu KK; Wu TJ; Cheng K; Ren N; Cai TQ; Chen Q; Wang J; Wolff MS; Tong X; Holt TG; Waters MG; Hammond ML; Tata JR; Colletti SL
    J Med Chem; 2010 Mar; 53(6):2666-70. PubMed ID: 20184326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.
    Carballo-Jane E; Gerckens LS; Luell S; Parlapiano AS; Wolff M; Colletti SL; Tata JR; Taggart AK; Waters MG; Richman JG; McCann ME; Forrest MJ
    J Pharmacol Toxicol Methods; 2007; 56(3):308-16. PubMed ID: 17643322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonist lead identification for the high affinity niacin receptor GPR109a.
    Gharbaoui T; Skinner PJ; Shin YJ; Averbuj C; Jung JK; Johnson BR; Duong T; Decaire M; Uy J; Cherrier MC; Webb PJ; Tamura SY; Zou N; Rodriguez N; Boatman PD; Sage CR; Lindstrom A; Xu J; Schrader TO; Smith BM; Chen R; Richman JG; Connolly DT; Colletti SL; Tata JR; Semple G
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4914-9. PubMed ID: 17588745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acyl hydroxypyrazoles as novel agonists for high-affinity nicotinic acid receptor GPR109A: WO2008051403.
    Shen HC
    Expert Opin Ther Pat; 2009 Aug; 19(8):1149-55. PubMed ID: 19566484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.
    Shen HC; Ding FX; Deng Q; Wilsie LC; Krsmanovic ML; Taggart AK; Carballo-Jane E; Ren N; Cai TQ; Wu TJ; Wu KK; Cheng K; Chen Q; Wolff MS; Tong X; Holt TG; Waters MG; Hammond ML; Tata JR; Colletti SL
    J Med Chem; 2009 Apr; 52(8):2587-602. PubMed ID: 19309152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of GPR109A agonists in the treatment of dyslipidaemia.
    Wanders D; Judd RL
    Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazole derivatives as partial agonists for the nicotinic acid receptor.
    van Herk T; Brussee J; van den Nieuwendijk AM; van der Klein PA; IJzerman AP; Stannek C; Burmeister A; Lorenzen A
    J Med Chem; 2003 Aug; 46(18):3945-51. PubMed ID: 12930155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b.
    Semple G; Skinner PJ; Cherrier MC; Webb PJ; Sage CR; Tamura SY; Chen R; Richman JG; Connolly DT
    J Med Chem; 2006 Feb; 49(4):1227-30. PubMed ID: 16480258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
    Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
    Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
    Offermanns S
    Trends Pharmacol Sci; 2006 Jul; 27(7):384-90. PubMed ID: 16766048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.